Freeline Therapeutics Holdings Plc Stock Price, News & Analysis

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) announced a change to its American Depositary Shares (ADS) ratio, adjusting from 1:1 to 1:15 ahead of May 12, 2023. This reverse ADS split aims to help the company comply with Nasdaq's minimum bid price requirement. Current holders of certificated ADSs must surrender them for a new ADS in exchange for every fifteen existing ADSs. Uncertificated holders will receive automatic exchanges. The change is expected to proportionally increase Freeline’s ADS trading price, although no assurance is provided regarding future price levels. Despite this adjustment, there will be no impact on the underlying ordinary shares. The company continues to focus on developing transformative gene therapies, particularly its candidate FLT201 for treating Gaucher disease type 1.

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) announced that CEO Michael Parini will present at the 22nd Annual Needham Virtual Healthcare Conference from April 17-20, 2023. The presentation is scheduled for 8 a.m. ET on April 19. Freeline's senior management will also hold one-on-one investor meetings during the event.

A live webcast of the presentation can be accessed through the Investors section of Freeline’s website, with an archived replay available for approximately 90 days afterward.

Freeline focuses on developing gene therapies for chronic debilitating diseases, utilizing their proprietary AAV vector technology. The company is progressing with FLT201, a novel gene therapy candidate currently in a Phase 1/2 clinical trial for Gaucher disease type 1. Freeline's operations extend from the UK to the United States.

Freeline Therapeutics Holdings reported its financial results for the year ending December 31, 2022, highlighting a focus on FLT201, a gene therapy for Gaucher disease type 1. The company anticipates initial data from Phase 1/2 trials of FLT201 in Q3 2023, showcasing its commitment to improving patient outcomes. In contrast, the development of FLT190 has been paused to streamline operations and extend its cash runway, anticipating cash sufficiency into Q2 2024. Financially, unrestricted cash fell from $117.7 million in 2021 to $47.3 million in 2022, with a net loss of $89.0 million, down from $140.4 million the prior year.

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) has announced a live conference call and webcast scheduled for April 4, 2023, at 8:00 a.m. ET to discuss its full year 2022 financial results and provide corporate updates. Participants are encouraged to join the call 10 minutes early, and a live webcast will be available on the company's website, with a replay for 90 days post-event. Freeline is focused on gene therapies using adeno-associated virus vectors to treat chronic diseases such as Fabry and Gaucher diseases, advancing innovative one-time treatments for patients.

LONDON, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) has finalized the sale of its German subsidiary, Freeline Therapeutics GmbH, to Ascend Gene and Cell Therapies Ltd. for $25 million, subject to adjustments. The deal includes rights to related intellectual property, with Freeline retaining rights to its AAVS3 capsid. An intellectual property agreement was established to assign certain rights to Ascend while ensuring Freeline can still develop its product candidates. Additionally, a transition services agreement is in place for 18 months, allowing Freeline access to critical development capabilities.